The U.S. Supreme Court recieved an amicus brief on FDA regulation.

This two-volume collection of key papers by leading scholars provides a comprehensive perspective on the evaluation and performance of risk regulation policies.

This monograph assesses how the adverse health implications associated with regulatory costs can affect mortality risk by considering a broad group of federal regulations.

This volume examines state regulations for hazard warnings--for foods, drugs, and medical devices--and demonstrates why a federal warnings approach would be preferable.

The U.S. Supreme Court recieved an amicus brief on FDA regulation.